IL6 and neoplasm: This process is further driven by factors such as transforming growth factor‐beta (TGF‐β), interleukin‐6 (IL‐6), and receptor activator of nuclear factor kappa‐Β ligand (RANKL), which not only enhance tumor cell survival and proliferation but also contribute to immune evasion and chronic inflammation [14, 15].